Keywords: Cell Therapeutics, Pixuvri, Non-Hodgkin's lymphmoma, NDAm USA, FDA

Cell Therapeutics updates on Pixuvri

Article | 30 January 2012

Print This

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its New Drug Application for Pixuvri ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in